相关实验视频

Updated: Sep 18, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

氧化脂的降解由 lysosomal 脂酶 A2 调节肺纤维化

Doyun Kwak¹, Song Ling¹, Natalya Subbotina¹

¹Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.

American journal of physiology. Lung cellular and molecular physiology

|June 26, 2025

概括

lysosomal phospholipase A2 (LPLA2) 在肺巨细胞中降解氧化脂 (oxPLs),防止纤维化. 增强LPLA2活性可能为肺纤维化提供治疗策略.

科学领域:

肺部医学肺部医学
脂质代谢脂质代谢是什么
细胞生物学细胞生物学

背景情况:

氧化脂 (oxPLs) 与肺纤维化病原发生有关.
将oxPLs与纤维化联系在一起的确切机制包括上皮损伤,脂质积累和巨细胞激活.
lysosomal phospholipase A2 (LPLA2) 催化氧PLs,特别是在膜巨细胞中.

研究的目的:

研究LPLA2在调节巨细胞内oxPL积累中的作用.
确定LPLA2活性是否影响肺纤维化发展.
探索LPLA2作为肺纤维化的潜在治疗点.

主要方法:

使用了野生型 (WT) 和LPLA2-null小鼠,受到白素诱导的肺损伤.
评估了肺纤维化严重程度,支气管支气管洗 (BAL) 细胞脂质积累和巨细胞蛋白激活.
使用骨髓衍生的巨细胞进行了体外研究,以及对LPLA2.2的体内过度表达研究.

主要成果:

与WT小鼠相比,LPLA2-null小鼠显示细胞内脂质积累增加,BAL液TGFβ水平较高,以及受伤后肺纤维化恶化.
在体外,LPLA2的表达限制了oxPL的积累,并减轻了profibrotic巨细胞的激活.
在WT小鼠中,LPLA2的过度表达减少了脂质积累,减少了BALF TGFβ,并减弱了纤维化.

结论:

LPLA2通过调节膜细胞中的oxPL积累,在预防肺纤维化方面发挥着至关重要的作用.
准LPLA2活性是减轻肺损伤中纤维化反应的有希望的治疗策略.
在脂质代谢中LPLA2的功能为开发肺纤维化治疗提供了一条新的途径.

关键词:

灭症 (apoptosis) 是一种死亡的过程.纤维化纤维化巨细胞是一个巨细胞.脂酸是一种脂酸.

更多相关视频

Shotgun Lipidomics of Rodent Tissues

Shotgun Lipidomics of Rodent Tissues

Published on: November 18, 2022

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

相关概念视频

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Asymmetric Lipid Bilayer

Asymmetric Lipid Bilayer

Biological membranes show uneven distribution of different types of lipids in the inner and outer layers, resulting in transverse asymmetric membranes. The treatment of the erythrocyte membrane with the enzyme phospholipase confirmed the asymmetric nature of the lipid bilayer. The enzyme hydrolyzes lipids into fatty acids and hydrophilic groups. The phospholipase acts only on the outer layer of the membrane, while the inner layer remains intact. The phospholipase treatment resulted in 80%...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Inflammation

Inflammation

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...